0QCO.LSE Pharming Group N.V.
- Market cap
- EUR 501M
- P/E
- 53.6x
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.
Is 0QCO.LSE undervalued?
Graham numberThe Graham number of Pharming Group N.V. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pharming Group N.V. fundamental analysis
No fundamental analysis for Pharming Group N.V. yet.
Pharming Group N.V. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treat…
Full company profilePharming Group N.V. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pharming Group N.V. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15.9M | 89.6M | 135M | 169M | 186M | - | - | - |
| Gross Profit | 11.2M | 77.2M | 113M | 148M | 165M | - | - | - |
| Operating Income | -11.5M | 21.9M | 38.0M | 60.9M | 66.7M | - | - | - |
| Net Income | -17.5M | -76.2M | 25.0M | 36.2M | 33.0M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | 127M | 166M | 214M | 228M | 341M | - | - | - |
| Total Liabilities | 99.3M | 150M | 153M | 124M | 191M | - | - | - |
| Shareholders' Equity | 27.5M | 16.1M | 61.8M | 105M | 149M | - | - | - |
| Cash & Short-term Investments | 31.9M | 58.7M | 80.3M | 66.3M | 167M | - | - | - |
| Total Debt | 41.0M | 59.6M | 37.4M | 4.36M | 129M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.0M | 38.2M | 40.4M | 66.5M | 83.6M | 37.8M | 22.9M | - |
| Capital Expenditure | 1.19M | 3.25M | 2.50M | 22.7M | 4.66M | 10.7M | 1.38M | 0.00 |
| Ratios | ||||||||
| ROE | -63.8% | -473.3% | 40.5% | 34.6% | 22.1% | - | - | - |
| ROA | -13.8% | -45.9% | 11.7% | 15.9% | 9.7% | - | - | - |
| Net Profit Margin | -110.5% | -85.1% | 18.5% | 21.4% | 17.8% | - | - | - |
| Debt to Equity | 1.49x | 3.70x | 0.61x | 0.04x | 0.86x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pharming Group N.V. dividends
Pharming Group N.V. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.1:1 on Mar 5, 2013.
Who owns Pharming Group N.V.
- Insiders 0.95%
- Institutions 22.92%
- Public & others 76.13%
- Shares outstanding 639M
- Free float 673M
Pharming Group N.V. company profile
- Company name
- Pharming Group N.V.
- Ticker
- 0QCO.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 407
- Fiscal year end
- December
- Address
- Darwinweg 24, Leiden, Netherlands, 2333 CR
- Phone
- 31 71 524 7400
- Website
- pharming.com
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kd inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3Kd inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Pharming Group N.V. management
10- Mr. Kenneth Lynard EMBA, M.Sc.CFO & Co-Chief Executive Officer · born 1968
- Ms. Leverne Marsh BPHARMCo-CEO & Chief Commercial Officer
- Ms. Mireille Sanders M.Sc.Chief Operations Officer · born 1968
- Mr. Michael K. LevitanVP of Investor Relations & Corporate Communications
- Mr. Ruud Van Outersterp L.L.M.Chief Legal & Compliance Officer and Company Secretary · born 1964
- Ms. Ines Bernal B.A.Chief People Officer
- Dr. Anurag Relan M.D., MPHChief Medical Officer · born 1972
- Dr. Alexander Breidenbach M.B.A., Ph.D.Chief Business Officer · born 1963
- Dr. Magnus HanssonMedical Director · born 1976
- Dr. Bruno M. L. GiannettiConsultant · born 1952